With Japan’s rapidly aging population, the prevalence of knee osteoarthritis is expected to rise. This has led to an increased demand for non-surgical treatment options, such as knee hyaluronic acid ...

Moving Biotech Secures €7.6M France 2030 Grant for Pioneering First-In-Class Disease-Modifying Osteoarthritis Drug ...

Primary total hip and total knee replacements are among the most common and successful orthopedic procedures worldwide. These ...

Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee: Brisbane, California Saturday, April 5, 2 ...

Pacira Biosciences leads in non-opioid pain relief with Exparel & upcoming knee osteoarthritis therapy. Click here to read my ...

In this interview, Technology Networks spoke with Dr. Francesco Dell’Accio and Dr. Suzanne Eldridge to explore the impact of ...

France 2030 validates 4Moving Biotech's scientific pioneering approach This strategic support positions the 4P004 drug candidate at the forefront of knee osteoarthritis innovation This ...

Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a ...

Though frustrating and difficult, hip pain is often preventable—and even when it isn't, it's nearly always treatable.

Moving Biotech (4MB), a spin-off of 4P-Pharma developing the first potential disease-modifying drug (DMOAD) for knee osteoarthritis, announces that it has been awarded ?7.6 million in funding under ...